Chabiotech Co.,Ltd. (KOSDAQ:085660)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,600
+230 (1.32%)
Apr 10, 2026, 3:30 PM KST
Market Cap1.61T +145.1%
Revenue (ttm)1.27T +21.4%
Net Income-109.88B
EPS-1,637.00
Shares Out92.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume235,328
Average Volume405,051
Open17,600
Previous Close17,370
Day's Range17,430 - 17,750
52-Week Range9,260 - 23,950
Beta0.79
RSI44.89
Earnings DateMay 14, 2026

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 278
Stock Exchange KOSDAQ
Ticker Symbol 085660
Full Company Profile

Financial Performance

In 2025, Chabiotech's revenue was 1.27 trillion, an increase of 21.36% compared to the previous year's 1.05 trillion. Losses were -109.88 billion, 2206.6% more than in 2024.

Financial Statements